Eli Lilly’s Emgality shows positive Phase 3 results in treatment of migraine
Eli Lilly has announced positive results from the Phase 3 EVOLVE-1 and EVOLVE-2 trials looking into Emgality (galcanezumab-gnlm) for the treatment of episodic migraine.
The drug was found to reduce the number of migraine headache days patients experienced each month, in comparison to placebo.
Patients – who were categorised as either low-frequency (four to seven migraine days a month) or high-frequency (eight to 14 monthly migraine days a month) – were given either 120mg or 240mg doses of Lilly’s Emgality.
Both doses were found to reduce the number of migraine days in both the low-frequency and high-frequency subgroups in comparison to placebo.
Lilly Bio-Medicines Neurology Development vice-president Gudarz Davar commented: “Migraine causes people to suffer from substantial pain and impairment, no matter how frequently they occur.”
“These collective analyses of more than 1,700 patients with episodic migraine from our Phase 3 Emgality programme reflect our continued commitment to aid people living with this serious neurologic disorder.”
The FDA is also currently reviewing the monoclonal antibody, which specifically targets calcitonin gene-related peptide (CGRP), as a preventative treatment of episodic cluster headache in adults.
Eli Lilly and Boehringer Ingelheim have announced that the US Food and Drug Administration (FDA) …
Eli Lilly has announced topline results from the LIBRETTO-531 study assessing Retevmo (selpercatinib) as an …